| HIV Infections
Truvada vs Prezista
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Truvada vs Prezista with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrezista has a higher rate of injection site reactions vs Truvada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Prezista but not Truvada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Truvada
Prezista
At A Glance
Oral
Once daily
NRTI combination (FTC + TDF)
Oral
Once daily or Twice daily
HIV-1 protease inhibitor
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections Adults and pediatric patients weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; pediatric patients weighing 17 to <35 kg: weight-based lower-strength tablet (100 mg/150 mg, 133 mg/200 mg, or 167 mg/250 mg) once daily; CrCl 30-49 mL/min: one tablet every 48 hours; CrCl <30 mL/min or hemodialysis: not recommended.
HIV-1 Pre-Exposure Prophylaxis HIV-1 uninfected adults and adolescents weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; not recommended if CrCl <60 mL/min.
HIV-1 Infections (treatment-naive adults) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, no darunavir resistance) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, at least one darunavir resistance substitution) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pregnant patients) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pediatric patients, 3 to less than 18 years) Weight-based dosing with ritonavir, oral, with food. Dosage based on body weight and resistance status, not to exceed adult dose
Contraindications
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
- Co-administration with alfuzosin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin
- Co-administration with simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil for pulmonary arterial hypertension
- Co-administration with orally administered midazolam
- Co-administration with triazolam
Adverse Reactions
Most common (>=10%) Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, rash
Serious Severe acute exacerbations of hepatitis B, new onset or worsening renal impairment, immune reconstitution syndrome, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Allergic reaction including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, hepatic steatosis, hepatitis, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, proteinuria, asthenia
Most common (>=5%, treatment-naive) Diarrhea, headache, abdominal pain, rash, nausea, vomiting
Most common (>=5%, treatment-experienced) Diarrhea, nausea, rash, abdominal pain, vomiting
Serious Hepatotoxicity, severe skin reactions (Stevens-Johnson Syndrome, toxic epidermal necrolysis), acute pancreatitis, diabetes mellitus, hyperglycemia, immune reconstitution syndrome
Postmarketing Rhabdomyolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, crystal nephropathy, crystalluria
Pharmacology
FTC and TDF are both nucleoside analog reverse transcriptase inhibitors (NRTIs); each is converted intracellularly to an active triphosphate form that inhibits HIV-1 reverse transcriptase by competing with natural dNTP substrates and causing chain termination. No antagonism between FTC and TDF has been observed in cell culture combination studies.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Truvada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Prezista
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Truvada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Prezista
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Truvada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Prezista
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TruvadaView full Truvada profile
PrezistaView full Prezista profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.